PHPN.STU Galectin Therapeutics Inc
- Market cap
- -
- P/E
- -
- P/B
- 207.08x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is PHPN.STU undervalued?
Graham numberThe Graham number of Galectin Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Galectin Therapeutics Inc fundamental analysis
No fundamental analysis for Galectin Therapeutics Inc yet.
Galectin Therapeutics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
Galectin Therapeutics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Galectin Therapeutics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -13.6M | -17.7M | -23.4M | -30.2M | -38.4M | -38.1M | -42.4M | -20.1M | -16.1M |
| EBITDA | -13.6M | -13.2M | -23.4M | -30.0M | -37.7M | -38.2M | -41.5M | -23.5M | -20.3M |
| Net Income | -13.9M | -17.6M | -23.5M | -30.5M | -38.8M | -41.1M | -47.0M | -30.8M | -28.3M |
| EPS | -0.34 | -0.31 | -0.41 | -0.51 | -0.65 | -0.66 | -0.74 | -0.47 | -0.43 |
| Balance Sheet | |||||||||
| Total Assets | 9.01M | 48.5M | 29.6M | 41.8M | 21.3M | 28.2M | 17.5M | 19.5M | 14.8M |
| Total Liabilities | 2.11M | 2.87M | 5.41M | 39.2M | 53.5M | 88.4M | 121M | 146M | 152M |
| Shareholders' Equity | 6.90M | 45.6M | 24.2M | 2.62M | -32.2M | -60.2M | -103M | -126M | -137M |
| Cash & Short-term Investments | 8.25M | 47.5M | 27.1M | 39.6M | 18.6M | 25.7M | 15.1M | 17.7M | 13.3M |
| Cash Flow | |||||||||
| Operating Cash Flow | -10.2M | -12.2M | -20.6M | -24.3M | -31.1M | -33.0M | -41.8M | -23.9M | -12.6M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -10.2M | -12.2M | -20.6M | -24.3M | -31.1M | -33.0M | -41.8M | -23.9M | -12.6M |
| Ratios | |||||||||
| ROE | -201.5% | -38.6% | -97.0% | -1,166.9% | - | - | - | - | - |
| ROA | -154.3% | -36.3% | -79.3% | -73.0% | -182.2% | -145.6% | -268.9% | -157.9% | -191.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Galectin Therapeutics Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 394K | 0.01 | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Galectin Therapeutics Inc
Ownership data of Galectin Therapeutics Inc is not available yet.
Galectin Therapeutics Inc company profile
- Company name
- Galectin Therapeutics Inc
- Ticker
- PHPN.STU
- Exchange
- Stuttgart Exchange
- Sector
- -
- Industry
- -
- Fiscal year end
- December
- Address
- Website
- -